LILY WANG LAB NTHU

 

Area: MOST Inno Zone

Booth No: N915

Website: https://beliminatenthu.carrd.co/

 

Exhibitor Profile

 

KIF2Ci is a first-in-class small-molecule inhibitor that specifically targets KIF2C, a member of the kinesin-13 family. By blocking microtubule depolymerization, KIF2Ci disrupts mitosis and triggers apoptosis in paclitaxel-resistant cancer cells. It has demonstrated synergistic effects when combined with more than 50% clinically used chemotherapeutic agents, enhancing therapeutic efficacy and overcoming chemoresistance through synthetic lethality. As a promising chemosensitizer, KIF2Ci may offer a valuable new treatment option for patients with recurrent or metastatic breast cancer who have failed previous chemotherapy.

 

Brands

 

Beliminate Biomedical Technology

 

Video

 

• 

  Introduction of Beliminate from NTHU

 

 

Exhibit Products

 

• 

  KIF2Ci

 

Exhibitor Press Release

 

• NTHU team achieves breakthrough in breast cancer chemoresistant targeted therapy 2025-06-18

 

 

 

back